Unlike statins, GLP-1 RA not only exhibit CV benefits but also improve CKD outcomes, reduce the incidence of HHF, and lower all-cause mortality—reflecting distinct effects at multiple organ levels [14]. The gene discussed is GCG; the disease is chronic kidney disease.